Loading clinical trials...

The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures | Clinical Trials | Clareo Health

WITHDRAWNPHASE1/PHASE2

The Role of Sugammadex in Posotoperative Urinary Retention in Patients Undergoing Pelvic Floor Reconstructive Procedures

A Randomized Clinical Trial to Determine the Effect of Transient Postoperative Urinary Retention Using Sugammadex (4 Mg X Kg) Versus Glycopyrrolate and Neostigmine (0.01 Mg/kg - 50mg/kg) in Patients Undergoing Vaginal Hysterectomies with and Without Pelvic Organ Prolapse Procedures: a Pilot Study

NCT05664633•West Virginia University

View on ClinicalTrials.gov

Summary

The Investigator will perform a single-institution randomized double-blinded controlled trial comparing intraoperative Sugammadex vs. standard dose of glycopyrrolate/neostigmine combination for participants undergoing a total vaginal hysterectomy with or without pelvic organ prolapse procedures under general endotracheal anesthesia.

Eligibility

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•female patients undergoing a vaginal hysterectomy with the indications of pelvic organ prolapse or abnormal uterine bleeding

Exclusion Criteria

•Patients who are already known to have voiding dysfunction
•Patients who have a contraindication or intolerance to any of the drugs used in the study
•Has a medical condition or surgical procedure that precludes reversal of neuromuscular block at the end of surgery.
•Has a neuromuscular disorder(s) that may affect neuromuscular block and/or trial assessments.
•Is dialysis-dependent or has severe renal insufficiency, defined as estimated creatinine clearance of \<30 mL/min.
•Has or is suspected of having a personal history or family history (parents, grandparents, or siblings) of malignant hyperthermia.
•Has or is suspected of having an allergy (e.g., hypersensitivity and/or anaphylactic reaction) to study treatments or its/their excipients, to opioids/opiates, muscle relaxants or their excipients, or other medication(s) used during general anesthesia.
•Has received or is planned to receive toremifene within 24 hours before or within 24 hours after study medication administration.
•Has any condition that would contraindicate the administration of study medication.
•Is pregnant, is attempting to become pregnant, or is lactating.
+6 more criteria

Key Dates

Start Date

August 1, 2023

Primary Completion Date

June 1, 2024

Completion Date

June 1, 2024

Last Updated

March 7, 2025

Conditions

Postoperative Urinary Retention

Interventions

Sugammadex

DRUG

Acupuncture for Postoperative Urinary Retention After Hemorrhoidectomy: a Randomized Controlled Trial

NCT05898919

Postoperative ComplicationsPostoperative Urinary Retention

View study

WITHDRAWNNA

Void Trials After Two Voiding Trials (TVT)

NCT03937531

Postoperative Voiding DysfunctionPostoperative Urinary Retention

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions